Polaris Group, a privately held multinational biopharmaceutical drug company, specializes in the research and development of protein drugs to treat cancer and other debilitating diseases in humans.

Polaris' lead project is ADI-PEG 20, a biotherapeutic agent that is in advanced clinical development for the treatment of hepatocellular carcinoma and metastatic melanoma.

Polaris is collaborating with EnzymeRx in the development of Uricase-PEG 20 for the treatment of gout, tumor lysis syndrome, and other diseases related to hyperuricemia.

Polaris is also researching and developing other biotherapeutic agents and has a small molecule drug program. The latter utilizes a rational structure-based approach for the design of novel compounds that inhibit the biological function of cancer-related protein targets.

Biotechnology

Pharmaceutical

Polaris Pharmaceuticals

Shaw T. Chen

Eric Van Rumund

Richard E. Showalter

Nien-Tsu Chen

The Leadership Team at Polaris Pharmaceuticals oversees the strategic direction and overall management of the company. This includes guiding research and development initiatives, making critical business decisions, and ensuring the alignment of projects with the company's goals. They are responsible for fostering collaborations, such as the partnership with EnzymeRx, and driving innovation in developing biopharmaceutical treatments for cancer and other debilitating diseases.

Leadership Team

About

Team members

Other teams at Polaris Pharmaceuticals

Research and Development Team